LEADER 04149namaa2200997uu 4500
001 doab101322
003 oapen
005 20230714
006 m o d
007 cr|mn|---annan
008 230714s2023 xx |||||o ||| 0|eng d
020 |a 9783036578422 
020 |a 9783036578439 
020 |a books978-3-0365-7843-9 
024 7 |a 10.3390/books978-3-0365-7843-9  |2 doi 
040 |a oapen  |c oapen 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
720 1 |a Bazan-Socha, Stanislawa  |4 edt 
720 1 |a Bazan-Socha, Stanislawa  |4 oth 
245 0 0 |a Pathogenesis and Novel Therapeutics in Asthma 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2023 
300 |a 1 online resource (168 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |f Unrestricted online access  |2 star 
520 |a Asthma is a prevalent chronic inflammatory disease of the airways with complex etiology and mechanistic pathways and variable clinical presentation. Such heterogeneity renders the search for targeted therapies difficult. Currently, the best-known disease phenotype with tailored biological treatment is eosinophilic asthma; however, even in some of these patients, anti-IL5 treatment is ineffective. Furthermore, about a quarter of patients, especially those with a severe phenotype, develop progressive and irreversible airway obstruction, leading to persistent symptoms despite optimized treatment. Therefore, new therapeutic approaches are still needed, particularly in severe asthma. The Special Issue presents asthma research focusing on modern personalized therapeutic approaches. Particular interest is directed to novel asthma biomarkers, including molecular and epigenetic ones, shining new light on pathogenesis, phenotyping, and customized therapy in various airway inflammatory patterns of the disease. In addition, research articles on airway epithelial cell dysfunction, airway remodeling, and the overlap between asthma and chronic obstructive pulmonary disease are welcomed. Stanislawa Bazan-Socha (Guest Editors) 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |u https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine and Nursing  |2 bicssc 
653 |a 12-LO 
653 |a airway epithelium 
653 |a airway inflammation 
653 |a airway remodeling 
653 |a allergen immunotherapy 
653 |a allergic inflammation 
653 |a allergic rhinitis 
653 |a allergy 
653 |a anti-inflammatory 
653 |a asthma 
653 |a Bcl10 
653 |a biomarkers 
653 |a BLT2 
653 |a bronchial asthma 
653 |a bronchial epithelial cells 
653 |a bronchial fibroblasts 
653 |a Candida albicans 
653 |a CBA assay 
653 |a cellular compartmentalization 
653 |a children 
653 |a component-resolved diagnosis 
653 |a cytokines 
653 |a diagnosis 
653 |a efficacy 
653 |a eosinophils 
653 |a exacerbation 
653 |a exhaled breath condensate 
653 |a extracellular vesicles 
653 |a factors 
653 |a fibrosis 
653 |a fungal sensitization 
653 |a G-CSF 
653 |a IL-17A 
653 |a immune health 
653 |a investigational 
653 |a mediation effect 
653 |a miRNA 
653 |a miRNAs 
653 |a n/a 
653 |a natural therapeutics 
653 |a neutrophil 
653 |a NF-κB pathway 
653 |a oxidative stress 
653 |a Phase I 
653 |a Phase II 
653 |a proinflammatory 
653 |a prostacyclin 
653 |a RCT 
653 |a serum 
653 |a severe asthma 
653 |a sublingual immunotherapy 
793 0 |a DOAB Library. 
856 4 0 |u https://directory.doabooks.org/handle/20.500.12854/101322  |7 0  |z Open Access: DOAB: description of the publication 
856 4 0 |u https://mdpi.com/books/pdfview/book/7416  |7 0  |z Open Access: DOAB, download the publication